[Peripheral corneal melting syndrome in psoriatic arthritis treated with adalimumab]

Rev Bras Reumatol. 2015 Jul-Aug;55(4):387-9. doi: 10.1016/j.rbr.2013.10.007. Epub 2014 Oct 5.
[Article in Portuguese]

Abstract

Peripheral corneal melting syndrome is a rare immune condition characterized by marginal corneal thinning and sometimes perforation. It is associated with rheumatic and non-rheumatic diseases. Few cases of peripheral corneal melting have been reported in patients with psoriasis. The pathogenesis is not fully understood but metalloproteinases may play a pathogenic role. Anti-TNF therapy has shown to decrease skin and serum metalloproteinases levels in psoriasis. We report a 61-year-old man with peripheral corneal melting syndrome associated with psoriatic arthritis who received Adalimumab to control skin and ocular inflammation. To our knowledge, this is the first case report of peripheral corneal melting syndrome in psoriatic arthritis treated with Adalimumab showing resolution of skin lesions and complete healing of corneal perforation in three months.

Keywords: Adalimumab; Adalimumabe; Artrite psoriásica; Corneal perforation; Perfuração da córnea; Psoriatic arthritis.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / therapeutic use*
  • Anti-Inflammatory Agents / therapeutic use*
  • Arthritis, Psoriatic / complications*
  • Corneal Perforation / drug therapy*
  • Corneal Perforation / etiology*
  • Humans
  • Male
  • Middle Aged

Substances

  • Anti-Inflammatory Agents
  • Adalimumab